Repligen's Endostatin B (platelet factor-4)
Executive Summary
INDs for the recombinant angiogenesis inhibitor product will be filed this year for treatment of Kaposi's sarcoma and the neutralization of heparin following cardiopulmonary bypass surgery, President Sanford Smith reported Jan. 8 at the Hambrecht & Quist health care conference. Repligen says the Kaposi's indication "may get a fast track at FDA." The company estimates that nearly all 600,000 bypass patients annually would be candidates for Endostatin.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth